Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide dose optimization for maintenance treatment of recurrent aphthous stomatitis
ChiCTR2400087537Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of thalidomide in aphthosis (RAS) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Recurrence interval. Started Jul 2024; status: recruiting.
02
Drugs
thalidomide
03
Conditions
aphthosis (RAS)
Beyond the preview
Go deeper on ChiCTR2400087537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087537.